CAJ | 학술논문

[目的]探讨胰腺类癌的临床和病理学特点.[方法]对1997年1月1日至2007年12月31日期间手术治疗的8例胰腺类癌临床病理资料(如肿瘤标志物、病理免疫组织化学染色、伴发其他肿瘤、误诊率、肿瘤转移率、住院死亡率、手术根治率等)进行回顾性分析,并结合国内外文献探讨胰腺类癌的临床和病理学特点.[结果]肿瘤标志物CEA、CA199、CA125、CA72-4在胰腺类癌的表达阳性率分别为0%,25%,12.5%,0%,病理免疫组织化学染色Syn、CgA、NSE、CK阳性率分别为25%,62.5%,75%,75%.胰腺类癌伴发其他肿瘤为1/4.胰腺类癌误诊率较高.8例患者中有7例误诊为其它肿瘤.胰腺类癌肿瘤总的转移率为50%,住院死亡率为37.5%,而手术根治率为62.5%.[结论]胰腺类癌误诊率高,常规血液肿瘤标志对早期发现胰腺类癌意义不大,确诊需要病理病理,临床预后较差.
[목적]탐토이선유암적림상화병이학특점.[방법]대1997년1월1일지2007년12월31일기간수술치료적8례이선유암림상병리자료(여종류표지물、병리면역조직화학염색、반발기타종류、오진솔、종류전이솔、주원사망솔、수술근치솔등)진행회고성분석,병결합국내외문헌탐토이선유암적림상화병이학특점.[결과]종류표지물CEA、CA199、CA125、CA72-4재이선유암적표체양성솔분별위0%,25%,12.5%,0%,병리면역조직화학염색Syn、CgA、NSE、CK양성솔분별위25%,62.5%,75%,75%.이선유암반발기타종류위1/4.이선유암오진솔교고.8례환자중유7례오진위기타종류.이선유암종류총적전이솔위50%,주원사망솔위37.5%,이수술근치솔위62.5%.[결론]이선유암오진솔고,상규혈액종류표지대조기발현이선유암의의불대,학진수요병리병리,림상예후교차.
[Objective] To explore the clinical pathological characteristics and treatment of pancreatic careinoid. [Methods] Eight patients with pancreatic careinoid were recruited between January in 1997 and December in 2007 for retrospective analysis which involved tumor markers, inanunohistostaining, accompanied with other tumors, misdiagnosis, metastasis, in-hospital mortality rate, and so on. The relevant literatures were simultaneously reviewed to comprehend the clinical pathological characteristics of pancreatic carcinoid. [Results] Tumor markers CEA, CA199, CA125, and CA72-4 in pancreatic carcinoid were 0%, 25%, 12.5%, and 0%, respectively. Specimen immanohistostaining Syn, CgA, NSE, and CK in pancreatic carcinoid were 25%, 62.5%, 75%, and 75%, respectively. Two pancreatic carcinoids were accompanied by other tumors in 8 cases. The misdiagnosis rate of pancreatic carcinoid (7/8) was markedly high. Pancreatic carcinoid possessed high metastasis (50%), high in-hospital mortality rate (37.5%) and low radical operation undergone (62.5%). [Conclusions] Pancrcatic carcinoid was accompanied with high misdiagnosis rate and poor prognosis. Routine sero-markers did not help discover pancreatic carcinoid early. The final diagnosis depended on specimen immunohistostaining with Syn, CgA, NSE, and CK.